Zhejiang Hisun Pharmaceutical Co. Ltd.
http://www.hisunpharm.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zhejiang Hisun Pharmaceutical Co. Ltd.
The Quality Lowdown: Rewarding Your Best Quality Critics
Lupin hires former nemesis at FDA, how Baker exposed Hisun’s ‘full investigation,’ Cetylite’s many methods for overcoming OOS results, old school inspection-driven recalls at Vitae Enim Vitae Scientific and a critique of Catalent filling line’s non-deliberate response to the pandemic.
Oncology, Domestic Firms Dominate New China Approvals As Innovation Gathers Pace
China's top regulator grants approvals to a record number of novel drugs, including multiple oncology products from domestic companies, which are increasingly shifting to innovation, supported by positive regulatory changes over the past few years.
Tech Transfer Roundup: Hoth Teams With VCU On Therapy To Block COVID-19 Replication
Pandemic-related collaborations between Hoth/VCU; Sorrento/Mt. Sinai Health; Audax/Northeastern U.; Alkido/U. of Maryland, Baltimore; Active Motif/Hisun BioRay/Fudan U. and more.
India Panel Favors Favipiravir, Tocilizumab As It Assesses COVID-19 Treatments
In a preliminary assessment of repurposed COVID-19 treatments by a government-appointed panel to assess the readiness and potential of a drug to be used in India, favipiravir and tocilizumab have emerged as front-runners. With Strides Pharma exporting the antiviral and Glenmark set to begin clinical trials, even the industry is supporting favipiravir, which is already in studies in Japan and China.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Hisun-Pfizer Pharmaceuticals Co., Ltd.